The Effect of Left Ventricular Assist Device Implantation on Serum Albumin, Total Protein and Body Mass: A Short-Term, Longitudinal Follow-Up Study

Güvenç, Tolga Sinan; Güzelburç, Özge; Ekmekçi, Ahmet; Erdoğan, Sevinç Bayer; Güvenç, Rengin Çetin; Velibey, Yalçın; Taşdemir, Müge; Ağustos, Semra; Orhan, Gökçen; Aka, Serap Aykut; Eren, Mehmet

doi:10.1016/j.hlc.2016.10.011

Cited by 8 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among those with hypoalbuminemia (the target cohort in this study), serum albumin level increased (i.e., albumin change >0 g/dl) following LVAD implantation in most patients (85%), which is consistent with a previous report 13 . The detailed mechanism remains uninvestigated, but hemodynamic improvement and improvement in hepatic perfusion and congestion would stabilize the above‐described condition of cardiac cachexia.…”

Section: Discussionsupporting

confidence: 88%

“…following LVAD implantation in most patients (85%), which is consistent with a previous report. 13 The detailed mechanism remains uninvestigated, but hemodynamic improvement and improvement in hepatic perfusion and congestion would stabilize the above-described condition of cardiac cachexia. Our finding that the incidence of early right ventricular failure was lower in the increased albumin group would support this hypothesis.…”

Section: F I G U R E Distribution Of Albumin Change During the First mentioning

confidence: 99%

See 1 more Smart Citation

Perioperative improvement in serum albumin level in patients with left ventricular assist device

Imamura

Combs

Siddiqi

et al. 2020

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Background: The negative impact of baseline hypoalbuminemia on clinical outcome following left ventricular assist device (LVAD) implantation is well known. However, the implications of perioperative change in serum albumin levels on post-LVAD outcomes remain uninvestigated. Methods: Among consecutive patients with baseline serum albumin <3.5 g/dl who received durable LVAD implantation between April 2014 and August 2017 and were followed for 1 year, the impact of perioperative change in serum albumin level from baseline to 3 months post-LVAD on the incidence of adverse events was investigated. Results: Sixty-eight patients (median 60 years and 69% male) were included. Serum albumin change was an independent predictor of the occurrence of adverse events with an adjusted hazard ratio of 0.32 (95% confidence interval, 0.13-0.78) and a cutoff change of 0.7 g/dl. Those with albumin increase >0.7 g/dl had higher 1-year freedom from adverse events (45% vs. 14%, p = .008), dominantly due to lower incidence of death or sepsis compared with those without (p < .05 for both). Conclusion: Among those with baseline hypoalbuminemia, a considerable perioperative increase in serum albumin levels following LVAD implantation was associated with lower mortality and morbidity. The implication of aggressive nutrition intervention on LVAD patients is the next concern.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: F I G U R E Distribution Of Albumin Change During the First mentioning

confidence: 99%

Perioperative improvement in serum albumin level in patients with left ventricular assist device

Imamura

Combs

Siddiqi

et al. 2020

Journal of Cardiac Surgery

View full text Add to dashboard Cite

show abstract

“…The impact of nutrition on metabolism is also directly reflected in the changes in the serum biochemical indicators. Serum TP is an important indicator of the level of protein metabolism in the liver ( 34 ). It is reported that serum TP level is inversely correlated with protein deposition in skeletal muscle tissues under the same intake of dietary nutrients ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Effects of Inorganic or Amino Acid-Chelated Zinc on Mouse Myoblast Growth in vitro and Growth Performance and Carcass Traits in Growing-Finishing Pigs

et al. 2022

View full text Add to dashboard Cite

This study aimed to investigate the effects of the supplementation of different sources of zinc on mouse myoblast growth in vitro and the growth performance and carcass traits in growing-finishing pigs. In the in vitro trial, 25 or 75 mM zinc sulfate (ZnSO4), methionine-chelated zinc (ZnMet), and glycine-chelated zinc (ZnGly) were co-cultured with the myoblast during proliferation and differentiation. The results showed that the amino acid-chelated zinc supplementation, especially ZnMet, enhances cell proliferation and differentiation in mouse myoblast, and regulates the distribution in S and G2/M phases (P < 0.05). Meanwhile, the protein expression levels of the mammalian target of rapamycin pathways were up-regulated after treatment with 25 μM ZnMet (P < 0.05), which is consistent with the results of the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway in the transcriptome analysis. In the in vivo trial, 27 Duroc × (Landrace × Large White) pigs with an initial average weight of 31.62 ± 0.36 kg were divided into three groups with nine replicates per treatment. The dietary treatment groups were as follows: (1) ZnSO4 group, basal diet +75 mg/kg ZnSO4; (2) ZnMet group, basal diet +75 mg/kg ZnMet; and (3) ZnGly group, basal diet +75 mg/kg ZnGly. The whole trial lasted for 75 days. Increased final body weight, average daily gain, and decreased F/G were noted in the ZnMet group (P < 0.05). Moreover, the ZnMet group had higher carcass weight and loin eye area (P = 0.05). The ZnMet and ZnGly group both had lower serum total protein (P < 0.05), while the ZnMet group had higher serum alkaline phosphatase (P < 0.05). Also, the addition of ZnMet showed higher concentrations of zinc and iron in muscle, kidney, and serum (P < 0.05), improving the deposition and availability of micronutrients. In conclusion, amino acid-chelated zinc, particularly ZnMet, had the best effect, which could improve growth in vitro and increase growth performance while boosting bioavailability in growing-finishing pigs, ultimately, enhancing muscle mass, providing a theoretical basis and guidance for the future use of amino acid-chelated zinc to effectively replenish energy in animal nutrition and production.

show abstract

“…It is presently unknown to what degree the skeletal muscle wasting (both low mass and tissue quality) of advanced systolic HF might be reversible with correction of the HF syndrome, and there is a paucity of data about the patterns of weight change in patients both before and following LVAD implantation 16–22 . It is also unclear what metabolic factors or biomarkers might promote the prevention and reversal of skeletal muscle wasting.…”

Section: Introductionmentioning

confidence: 99%

“…[13][14][15] It is presently unknown to what degree the skeletal muscle wasting (both low mass and tissue quality) of advanced systolic HF might be reversible with correction of the HF syndrome, and there is a paucity of data about the patterns of weight change in patients both before and following LVAD implantation. [16][17][18][19][20][21][22] It is also unclear what metabolic factors or biomarkers might promote the prevention and reversal of skeletal muscle wasting. A recent prospective LVAD cohort analysis found that 52% of LVAD recipients were sarcopenic prior to implantation, with a gain of 2.3 kg in fat-free mass by dual X-ray absorptiometry in the first 3 months after LVAD implantation.…”

Section: Introductionmentioning

confidence: 99%

Body mass index and natriuretic peptides trends before and after left ventricular assist device

Schultz

Vest

Masotti

et al. 2023

JCSM Rapid Communications

View full text Add to dashboard Cite

Background It is unknown to what degree of sarcopenia related to heart failure (HF) is reversible with resolution of the HF syndrome. We evaluated whether (1) weight loss prior to left ventricular assist device (LVAD) is associated with pre‐operative sarcopenia as quantified on pre‐operative chest CTs and (2) determine the relationship between weight recovery (increase) after LVAD implantation and reduction of NT‐proBNP levels. Methods In a large single‐centre cohort (n = 502), CT measures of sarcopenia (pectoralis muscle mass indexed to body surface area and tissue attenuation) were correlated with pre‐LVAD BMI trend (n = 190). BMI and NT‐proBNP trends before and after LVAD implantation were evaluated (n = 403). Linear effects modelling was performed to test the association between NT‐proBNP and BMI trends. Results A downtrending BMI prior to LVAD was associated with pectoralis muscle tissue attenuation (P < 0.05). BMI declined prior to LVAD, declined further early post‐implant, and then increased between 100 and 300 days post‐implant (average per cent change in BMI in Year 1, 7.6%, 95% CI: 6.3–8.8%). NT‐proBNP decreased during the first 100 post LVAD days (−5.4%, 95% CI: −6.6 to −4.2%). Post‐LVAD NT‐proBNP and BMI trends were significantly associated, with a decrease of 1 unit log NT‐proBNP associated with an increase in BMI of 0.81 kg/m2 (CI: 0.53–1.09, P < .001). The rise in post‐LVAD BMI occurred after the reduction in NT‐proBNP levels. Patients who failed to gain weight post‐LVAD had the highest 6‐month post‐LVAD natriuretic peptides (lowest per cent BMI gain tertile NT‐proBNP: 2208 vs. highest 1635 pg/mL, P < 0.001). Conclusions Weight recovery during LVAD support occurs after the reduction in natriuretic peptide levels. Failure to gain weight during LVAD support was associated with persistently elevated natriuretic peptide levels. These data collectively suggest that recovery of body mass may be dependent upon recovery of the HF syndrome.

show abstract

The Effect of Left Ventricular Assist Device Implantation on Serum Albumin, Total Protein and Body Mass: A Short-Term, Longitudinal Follow-Up Study

Cited by 8 publications

References 19 publications

Perioperative improvement in serum albumin level in patients with left ventricular assist device

Perioperative improvement in serum albumin level in patients with left ventricular assist device

Comparison of the Effects of Inorganic or Amino Acid-Chelated Zinc on Mouse Myoblast Growth in vitro and Growth Performance and Carcass Traits in Growing-Finishing Pigs

Body mass index and natriuretic peptides trends before and after left ventricular assist device

Contact Info

Product

Resources

About